FIELD: health care and biotechnology.
SUBSTANCE: invention relates to the field of biotechnology and medicine, in particular to a strain of hybrid cultured Homo sapiens/Mus musculus cells Hu-C6D7-RBD, a producer of human monoclonal antibodies specific to the RBD domain S of the SARS-CoV-2 virus protein.
EFFECT: invention enables to expand the range of agents of human monoclonal antibodies, specific to the RBD domain S of the SARS-CoV-2 virus protein, with virus neutralizing activity, which can be used to accumulate monoclonal immunoglobulin raw materials for the subsequent production of drugs.
1 cl, 8 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HOMO SAPIENS/MUS MUSCULUS 1B9C7 HYBRID CULTURED CELL STRAIN: PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE PROTEOLYTIC DOMAIN OF BOTULINUM TYPE A TOXIN | 2021 |
|
RU2783897C1 |
| Method for producing Chinese hamster ovary cell strain, being a producer of recombinant SARS-CoV-2 virus protein RBD, Chinese hamster ovary cell strain, producer of recombinant SARS-CoV-2 protein RBD, method for producing recombinant SARS-CoV-2 virus protein RBD, test system for enzyme immunoassay of human serum or plasma, and use thereof | 2020 |
|
RU2723008C1 |
| METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
| METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
| INTEGRATIVE PLASMID VECTOR PVEAL2-S-RBD, PROVIDING THE EXPRESSION AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS IN MAMMALIAN CELLS, THE RECOMBINANT CHO-K1-RBD CELL LINE STRAIN AND THE RECOMBINANT SARS-COV-2 RBD PROTEIN PRODUCED BY THE SPECIFIED STRAIN OF THE CELL LINE CHO-K1-RBD | 2021 |
|
RU2752858C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
| CONJUGATE OF THE RECEPTOR-BINDING DOMAIN (RBD) PROTEIN OF SARS-CoV-2 SURFACE GLYCOPROTEIN S WITH POLYGLUCIN-SPERMIDINE (PGS) POLYMER AND VACCINE COMPLEX AGAINST CORONAVIRUS INFECTION COVID-19 BASED ON THE SPECIFIED CONJUGATE AND PLASMID DNA PVAX-RBD | 2022 |
|
RU2781294C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| RECOMBINANT SARS-CoV-2 S PROTEIN RBD-BINDING PROTEIN | 2022 |
|
RU2778942C1 |
